Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 35,770 Shares of Stock

Posted by George Bondi on Jul 8th, 2026

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 35,770 shares of Werewolf Therapeutics stock in a transaction on Monday, July 6th. The shares were sold at an average price of $0.32, for a total transaction of $11,446.40. Following the completion of the sale, the director directly owned 107,429 shares of the company’s stock, valued at approximately $34,377.28. This trade represents a 24.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

On Tuesday, July 7th, Luke Evnin sold 107,429 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.31, for a total transaction of $33,302.99.
On Tuesday, June 9th, Luke Evnin sold 76,928 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total value of $28,463.36.
On Monday, June 8th, Luke Evnin sold 60,547 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total value of $24,218.80.
On Friday, June 5th, Luke Evnin sold 24,946 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.40, for a total value of $9,978.40.
On Thursday, June 4th, Luke Evnin sold 20,072 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.44, for a total value of $8,831.68.
On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total value of $12,494.58.
On Tuesday, June 2nd, Luke Evnin sold 29,595 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $13,317.75.
On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.47, for a total value of $37,815.73.
On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total value of $14,650.20.
On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.46, for a total transaction of $12,741.08.

Werewolf Therapeutics Stock Up 4.6%

HOWL stock traded up $0.02 during midday trading on Wednesday, reaching $0.36. 590,804 shares of the company’s stock traded hands, compared to its average volume of 539,946. The company has a market cap of $17.49 million, a price-to-earnings ratio of -0.29 and a beta of 0.30. The firm’s fifty day moving average price is $0.46 and its 200-day moving average price is $0.63. Werewolf Therapeutics, Inc. has a 52 week low of $0.27 and a 52 week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. Analysts forecast that Werewolf Therapeutics, Inc. will post -1.08 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on HOWL shares. Weiss Ratings lowered Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th. Wall Street Zen cut Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Werewolf Therapeutics presently has an average rating of “Hold” and a consensus price target of $3.75.

Get Our Latest Stock Report on Werewolf Therapeutics

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC bought a new stake in shares of Werewolf Therapeutics during the 1st quarter worth $79,000. Marshall Wace LLP bought a new position in Werewolf Therapeutics during the second quarter valued at about $113,000. Qube Research & Technologies Ltd purchased a new stake in Werewolf Therapeutics during the second quarter worth about $48,000. Jane Street Group LLC bought a new stake in Werewolf Therapeutics in the second quarter worth about $409,000. Finally, Bank of America Corp DE raised its position in Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after acquiring an additional 25,882 shares during the period. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.